|
1
|
Sajjad Y: Development of the genital ducts
and external genitalia in the early human embryo. J Obstet Gynaecol
Res. 36:929–937. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howitt BE and Nucci MR: Mesonephric
proliferations of the female genital tract. Pathology. 50:141–150.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mirkovic J, Sholl LM, Garcia E, Lindeman
N, MacConaill L, Hirsch M, Dal Cin P, Gorman M, Barletta JA, Nucci
MR, et al: Targeted genomic profiling reveals recurrent KRAS
mutations and gain of chromosome 1q in mesonephric carcinomas of
the female genital tract. Mod Pathol. 28:1504–1514. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Montalvo N, Redroban L and Galarza D:
Mesonephric adenocarcinoma of the cervix: A case report with a
three-year follow-up, lung metastases, and next-generation
sequencing analysis. Diagn Pathol. 14:712019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Menon S, Kathuria K, Deodhar K and Kerkar
R: Mesonephric adenocarcinoma (endometrioid type) of endocervix
with diffuse mesonephric hyperplasia involving cervical wall and
myometrium: An unusual case report. Indian J Pathol Microbiol.
56:51–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
da Silva EM, Fix DJ, Sebastiao APM,
Selenica P, Ferrando L, Kim SH, Stylianou A, Da Cruz Paula A,
Pareja F, Smith ES, et al: Mesonephric and mesonephric-like
carcinomas of the female genital tract: Molecular characterization
including cases with mixed histology and matched metastases. Mod
Pathol. 34:1570–1587. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mirkovic J, McFarland M, Garcia E, Sholl
LM, Lindeman N, MacConaill L, Dong F, Hirsch M, Nucci MR, Quick CM,
et al: Targeted genomic profiling reveals recurrent kras mutations
in mesonephric-like adenocarcinomas of the female genital tract. Am
J Surg Pathol. 42:227–233. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dierickx A, Goker M, Braems G, Tummers P
and Van den Broecke R: Mesonephric adenocarcinoma of the cervix:
Case report and literature review. Gynecol Oncol Rep. 17:7–11.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pors J, Segura S, Chiu DS, Almadani N, Ren
H, Fix DJ, Howitt BE, Kolin D, McCluggage WG, Mirkovic J, et al:
Clinicopathologic characteristics of mesonephric adenocarcinomas
and mesonephric-like adenocarcinomas in the gynecologic tract: A
multi-institutional study. Am J Surg Pathol. 45:498–506. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhatla N, Berek JS, Fredes MC, Denny LA,
Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J,
et al: Revised FIGO staging for carcinoma of the cervix uteri. Int
J Gynaecol Obstet. 145:129–135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klinkhamer PJ, Meerding WJ, Rosier PF and
Hanselaar AG: Liquid-based cervical cytology. Cancer. 99:263–271.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Devarashetty S, Chennapragada SS and
Mansour R: Not your typical adenocarcinoma: A case of mesonephric
adenocarcinoma of the cervix with fibroblast growth factor receptor
2 (FGFR2) mutation. Cureus. 14:e250982022.PubMed/NCBI
|
|
13
|
Jiang LL, Tong DM, Feng ZY and Liu KR:
Mesonephric adenocarcinoma of the uterine cervix with rare lung
metastases: A case report and review of the literature. World J
Clin Cases. 8:1735–1744. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tseng CE, Chen CH, Chen SJ and Chi CL:
Tumor rupture as an initial manifestation of malignant mesonephric
mixed tumor: A case report and review of the literature. Int J Clin
Exp Pathol. 7:1212–1217. 2014.PubMed/NCBI
|
|
15
|
Ribeiro B, Silva R, Dias R and Patrício V:
Carcinosarcoma of the uterine cervix: A rare pathological finding
originating from mesonephric remnants. BMJ Case Rep.
12:e2270502019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fregnani JH, Soares FA, Novik PR, Lopes A
and Latorre MR: Comparison of biological behavior between
early-stage adenocarcinoma and squamous cell carcinoma of the
uterine cervix. Eur J Obstet Gynecol Reprod Biol. 136:215–223.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jeong JH, Kim NY and Pyo JS: Analysis of
PAX8 immunohistochemistry in lung cancers: A meta-analysis. J
Pathol Transl Med. 54:300–309. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kenny SL, McBride HA, Jamison J and
McCluggage WG: Mesonephric adenocarcinomas of the uterine cervix
and corpus: HPV-negative neoplasms that are commonly PAX8, CA125,
and HMGA2 positive and that may be immunoreactive with TTF1 and
hepatocyte nuclear factor 1-β. Am J Surg Pathol. 36:799–807. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kadota K, Buitrago D, Lee MC,
Villena-Vargas J, Sima CS, Jones DR, Travis WD and Adusumilli PS:
Tumoral CD10 expression correlates with high-grade histology and
increases risk of recurrence in patients with stage I lung
adenocarcinoma. Lung Cancer. 89:329–336. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Howitt BE, Emori MM, Drapkin R, Gaspar C,
Barletta JA, Nucci MR, McCluggage WG, Oliva E and Hirsch MS: GATA3
is a sensitive and specific marker of benign and malignant
mesonephric lesions in the lower female genital tract. Am J Surg
Pathol. 39:1411–1419. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pors J, Cheng A, Leo JM, Kinloch MA, Gilks
B and Hoang L: A comparison of GATA3, TTF1, CD10, and calretinin in
identifying mesonephric and mesonephric-like carcinomas of the
gynecologic tract. Am J Surg Pathol. 42:1596–1606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee Y, Bae H and Kim HS: Endocervical
adenocarcinoma: Comprehensive histological review and
re-classification of 123 consecutive cases according to the updated
world health organization classification of female genital tumors.
Anticancer Res. 42:4627–4639. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Masjeed NMA, Khandeparkar SGS, Joshi AR,
Kulkarni MM and Pandya N: Immunohistochemical study of ER, PR, Ki67
and p53 in endometrial hyperplasias and endometrial carcinomas. J
Clin Diagn Res. 11:EC31–EC34. 2017.PubMed/NCBI
|
|
24
|
Meguro S, Yasuda M, Shimizu M, Kurosaki A
and Fujiwara K: Mesonephric adenocarcinoma with a sarcomatous
component, a notable subtype of cervical carcinosarcoma: A case
report and review of the literature. Diagn Pathol. 8:742013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bague S, Rodriguez IM and Prat J:
Malignant mesonephric tumors of the female genital tract: A
clinicopathologic study of 9 cases. Am J Surg Pathol. 28:601–607.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Silver SA, Devouassoux-Shisheboran M,
Mezzetti TP and Tavassoli FA: Mesonephric adenocarcinomas of the
uterine cervix: A study of 11 cases with immunohistochemical
findings. Am J Surg Pathol. 25:379–387. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mirkovic J, Olkhov-Mitsel E, Amemiya Y,
Al-Hussaini M, Nofech-Mozes S, Djordjevic B, Kupets R, Seth A and
McCluggage WG: Mesonephric-like adenocarcinoma of the female
genital tract: Novel observations and detailed molecular
characterisation of mixed tumours and mesonephric-like
carcinosarcomas. Histopathology. 82:978–990. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McCluggage WG: Mesonephric-like
Adenocarcinoma of the female genital tract: From Morphologic
observations to a well-characterized carcinoma with aggressive
clinical behavior. Adv Anat Pathol. 29:208–216. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matsuzaki S, Klar M, Matsuzaki S, Roman
LD, Sood AK and Matsuo K: Uterine carcinosarcoma: Contemporary
clinical summary, molecular updates, and future research
opportunity. Gynecol Oncol. 160:586–601. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kuburich NA, den Hollander P, Pietz JT and
Mani SA: Vimentin and cytokeratin: Good alone, bad together. Semin
Cancer Biol. 86:816–826. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wright AA, Howitt BE, Myers AP, Dahlberg
SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle
N, Jones RT, et al: Oncogenic mutations in cervical cancer: Genomic
differences between adenocarcinomas and squamous cell carcinomas of
the cervix. Cancer. 119:3776–3783. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xi Q, Kage H, Ogawa M, Matsunaga A,
Nishijima A, Sone K, Kawana K and Oda K: Genomic landscape of
endometrial, ovarian, and cervical cancers in Japan from the
database in the center for cancer genomics and advanced
therapeutics. Cancers (Basel). 16:1362023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mirkovic J, Schoolmeester JK, Campbell F,
Miron A, Nucci MR and Howitt BE: Cervical mesonephric hyperplasia
lacks KRAS/NRAS mutations. Histopathology. 71:1003–1005. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cancer Genome Atlas Research Network, .
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mjos S, Werner HMJ, Birkeland E, Holst F,
Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, et
al: PIK3CA exon9 mutations associate with reduced survival, and are
highly concordant between matching primary tumors and metastases in
endometrial cancer. Sci Rep. 7:102402017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McIntyre JB, Wu JS, Craighead PS, Phan T,
Köbel M, Lees-Miller SP, Ghatage P, Magliocco AM and Doll CM:
PIK3CA mutational status and overall survival in patients with
cervical cancer treated with radical chemoradiotherapy. Gynecol
Oncol. 128:409–414. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, He M, He T, Ouyang X, Shen X, Shi
W, Huang S, Xiang L, Zou D, Jiang W and Yang H: Integrated genomic
and transcriptomic analysis reveals the activation of PI3K
signaling pathway in HPV-independent cervical cancers. Br J Cancer.
130:987–1000. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Olson JM and Hallahan AR: p38 MAP kinase:
A convergence point in cancer therapy. Trends Mol Med. 10:125–129.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Samuels Y, Diaz LA Jr, Schmidt-Kittler O,
Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C,
Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion
of human cancer cells. Cancer Cell. 7:561–573. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cocco E, Scaltriti M and Drilon A: NTRK
fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin
Oncol. 15:731–747. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pasini L, Re A, Tebaldi T, Ricci G, Boi S,
Adami V, Barbareschi M and Quattrone A: TrkA is amplified in
malignant melanoma patients and induces an anti-proliferative
response in cell lines. BMC Cancer. 15:7772015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xie C, Chen Q and Shen Y: Mesonephric
adenocarcinomas in female genital tract: A case series. Medicine
(Baltimore). 100:e271742021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Janne PA, Riely GJ, Gadgeel SM, Heist RS,
Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, et
al: Adagrasib in non-small-cell lung cancer harboring a
KRASG12C mutation. N Engl J Med. 387:120–131. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang X, Allen S, Blake JF, Bowcut V,
Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ, et
al: Identification of MRTX1133, a noncovalent, potent, and
selective KRASG12D inhibitor. J Med Chem. 65:3123–3133.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hallin J, Bowcut V, Calinisan A, Briere
DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset
E, et al: Anti-tumor efficacy of a potent and selective
non-covalent KRASG12D inhibitor. Nat Med. 28:2171–2182.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Juric D, Rodon J, Tabernero J, Janku F,
Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M,
Gil-Martin M, et al: Phosphatidylinositol 3-kinase α-selective
inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors:
Results from the first-in-human study. J Clin Oncol. 36:1291–1299.
2018. View Article : Google Scholar : PubMed/NCBI
|
